PAM
FOLD

Premier Asset Management’s Amicus Therapeutics FOLD Stock Holding History

Premier Asset Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-29,067
Closed -$282K – 125
2018
Q4 		$282K Buy
+29,067
New +$320K 0.08% 122

Other funds holding FOLD

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Premier Asset Management's FOLD Position: Q1 2019 in Review

Premier Asset Management sold out of Amicus Therapeutics (FOLD) in Q1 2019, closing a stake of 29,067 shares — an estimated $282K sold.

Premier Asset Management first reported a position in FOLD in Q4 2018 and held it in 1 quarter. The position peaked at $282K in Q4 2018. 205 funds tracked by Wall St. Rank hold FOLD as of Q1 2019.

  • Premier Asset Management reported no remaining Amicus Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Premier Asset Management sold 29,067 Amicus Therapeutics shares in Q1 2019, an estimated $282K.
  • Premier Asset Management first reported a position in Amicus Therapeutics in Q4 2018 and held it in 1 quarter.
  • Premier Asset Management's Amicus Therapeutics position peaked at $282K in Q4 2018.
  • 205 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2019.

Based on Premier Asset Management's 13F filing for Q1 2019, filed 15 May 2019.